文献速递白内障与屈光手术眼底病与葡萄膜炎

蓝光滤过型人工晶状体视网膜保护作用的系统评价分析:证据局限性的解读

Analysis of a Systematic Review About Blue Light-Filtering Intraocular Lenses for Retinal Protection: Understanding the Limitations of the Evidence.
PubMed 文献 · JAMA Ophthalmol · 2019-01-01

本文分析2018年Cochrane系统评价(纳入51项随机对照试验、17个国家、超过5000眼)关于蓝光滤过型人工晶状体对视网膜保护作用的证据。由于结局测量方法不同、数据报告不完整及随访期差异,难以合并数据得出总体结论,且许多纳入研究存在内部真实性缺陷。结论是目前最佳临床研究证据不支持使用蓝光滤过型人工晶状体来赋予黄斑益处。

要点

  • 2018年Cochrane系统评价纳入51项RCT、超过5000眼,比较蓝光滤过与非蓝光滤过IOL。
  • 因测量方法异质、报告不全和随访期不同,数据难以合并得出总体结论。
  • 现有最佳证据不支持蓝光滤过IOL赋予黄斑益处,临床采用时需注意此证据局限。

核心结论

  • 使用蓝光滤过型人工晶状体赋予黄斑益处目前不被最佳可用临床研究证据支持。
  • 临床医生在临床实践中采用这类器械时,必须注意这一证据局限性。

研究设计与样本

  • 本文是对2018年Cochrane系统评价的分析与解读,该系统评价评估蓝光滤过型IOL提供黄斑健康与功能保护的疗效和安全性。
  • Cochrane系统评价纳入51项随机对照试验,在17个国家进行,受试者为接受白内障手术的成人,比较蓝光滤过型IOL与等效的非蓝光滤过型IOL。
  • 研究随访期为1个月至5年,合计评估超过5000眼的临床结局。

主要发现

  • 由于结局测量技术不同、数据报告不完整和/或随访期各异,跨试验合并数据以得出总体结论的能力有限。
  • 许多纳入研究在内部真实性方面存在显著缺陷,尤其涉及试验设计、实施和报告。

关键数值与推荐

  • Cochrane系统评价纳入51项随机对照试验,在17个国家进行,随访1个月至5年,合计超过5000眼。

临床怎么用

  • 临床医生在采用蓝光滤过型人工晶状体时,应知晓目前最佳临床研究证据并不支持其赋予黄斑益处。

局限性

  • 纳入研究使用不同的结局测量技术、数据报告不完整和/或随访期各异,限制了跨试验数据合并。
  • 许多纳入研究在试验设计、实施和报告方面存在显著内部真实性缺陷。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Cataract surgery, with intraocular lens (IOL) implantation, is the most common ocular surgical procedure worldwide. It has been suggested that IOLs that selectively attenuate short wavelength visible light (blue light-filtering IOLs) may be beneficial for macular health. Whether blue light-filtering IOLs impart retinal photoprotection is of public health relevance, particularly in the context of aging demographics and the increasing global prevalence of age-related macular degeneration. This review analyzes and interprets the key findings, including consideration of the implications for practice and future research, of a 2018 Cochrane systematic review that evaluated the efficacy and safety of blue light-filtering IOLs for providing protection to macular health and function. OBSERVATIONS: The Cochrane systematic review included 51 randomized controlled trials that were performed in 17 countries. The trials involved adults undergoing cataract surgery in which a blue light-filtering IOL was compared with an equivalent non-blue light-filtering IOL. Study follow-up periods ranged from 1 month to 5 years. Together, these studies considered clinical outcomes in more than 5000 eyes. There was limited ability to combine data across trials (to draw overall conclusions) because of the use of different measurement techniques for outcomes, incomplete reporting of data, and/or varied follow-up periods. We identified substantial shortcomings in the internal validity of many of the included studies, particularly regarding trial design, conduct, and reporting. We propose several avenues for improving the rigor of potential future research in the field, including developing a core set of outcome measures, the inclusion of sample size calculations, the masking of trial participants and outcome assessors, and prospective clinical trial registration. CONCLUSIONS AND RELEVANCE: Using blue light-filtering IOLs to impart benefits to the macula is currently not supported by the best available clinical research evidence, and it is important that clinicians are mindful of this evidence limitation when adopting these devices in clinical practice.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Downie LE, Wormald R, Evans J, et al. Analysis of a Systematic Review About Blue Light-Filtering Intraocular Lenses for Retinal Protection: Understanding the Limitations of the Evidence. JAMA Ophthalmol. 2019. PMID: 30789642. doi:10.1001/jamaophthalmol.2019.0019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。